valproic acid has been researched along with Carcinoma, Anaplastic in 24 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study investigated the mechanism underlying the antitumor activity of the histone deacetylases inhibitor valproic acid (VPA), alone and in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative (HS-1200), or the proteasome inhibitor lactacystin on cultured anaplastic thyroid carcinoma KAT-18 cells." | 7.75 | Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin. ( Kang, DY; Kim, SH; Kim, TH; Park, KJ; Park, MK; Suh, H; Yoo, YH, 2009) |
| " Histone deacetylase inhibitors such as valproic acid (VPA) are promising drugs for cancer therapy since they have been reported to have antiproliferative effects and to induce differentiation in carcinoma and leukemic cells." | 7.74 | Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. ( Aouali, N; Berchem, G; Bosseler, M; Brons, NH; Leners, B; Palissot, V; Schwartz, C; Wack, S, 2007) |
| "Valproic acid did not increase PTX-induced α-tubulin acetylation." | 5.43 | Valproic Acid as a Promising Co-Treatment With Paclitaxel and Doxorubicin in Different Ovarian Carcinoma Cell Lines. ( Fiedor, E; Gregoraszczuk, EL; Grzyb, E; Kwiecińska, P; Ptak, A; Taubøll, E, 2016) |
| "Valproic acid is a well-known antiepileptic drug that was recently discovered to have a wide-spectrum antitumoral action in several tumors." | 5.33 | Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. ( Angelucci, A; Bernardini, S; Bologna, M; Dolo, V; Federici, G; Gravina, GL; Miano, R; Millimaggi, D; Valentini, A; Vicentini, C, 2006) |
| "The present study investigated the effect of valproic acid (VPA) on the inhibition of RET signaling and induction of apoptosis in human thyroid carcinoma cells." | 3.81 | Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA). ( Dong, JD; Xu, D; Xu, Y; Ye, B; Zhang, Y; Zhang, YL; Zhu, SJ, 2015) |
| "The influence of the histone deacetylase (HDAC)-inhibitor, valproic acid (VPA), on bladder cancer cell adhesion in vitro was investigated in this paper." | 3.79 | HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions. ( Bartsch, G; Blaheta, RA; Haferkamp, A; Hudak, L; Juengel, E; Makarevic, J; Meyer dos Santos, S; Schneider, T; Wiesner, C, 2013) |
| " We found that 4 histone deacetylase inhibitors, trichostatin A (TSA), sodium butyrate (SB), valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA), all significantly induced EBV lytic cycle in EBV-positive gastric carcinoma cells (AGS/BX1, latency II) but only weakly induced in Burkitt lymphoma cells (AK2003, latency I) and did not induce in lymphoblastoid cells (LCLs, latency III)." | 3.76 | Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. ( Chiang, AK; Hui, KF, 2010) |
| "The present study investigated the mechanism underlying the antitumor activity of the histone deacetylases inhibitor valproic acid (VPA), alone and in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative (HS-1200), or the proteasome inhibitor lactacystin on cultured anaplastic thyroid carcinoma KAT-18 cells." | 3.75 | Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin. ( Kang, DY; Kim, SH; Kim, TH; Park, KJ; Park, MK; Suh, H; Yoo, YH, 2009) |
| " Histone deacetylase inhibitors such as valproic acid (VPA) are promising drugs for cancer therapy since they have been reported to have antiproliferative effects and to induce differentiation in carcinoma and leukemic cells." | 3.74 | Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines. ( Aouali, N; Berchem, G; Bosseler, M; Brons, NH; Leners, B; Palissot, V; Schwartz, C; Wack, S, 2007) |
| "The introduction of paclitaxel into multimodal therapy for anaplastic thyroid carcinoma has failed to improve overall survival." | 3.74 | Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. ( Boccuzzi, G; Catalano, MG; Fortunati, N; Poli, R; Pugliese, M, 2007) |
| "Despite successful primary treatment of nasopharyngeal carcinoma (NPC), the incidence of distant metastasis remains 25-34 %." | 2.80 | Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma. ( de Boer, JP; Greijer, AE; Huitema, AD; Juwana, H; Middeldorp, JM; Novalić, Z; Stoker, SD; Tan, IB; Verkuijlen, SA; Wildeman, MA, 2015) |
| "Valproic acid (VPA) is a HDACI that shows promising chemotherapeutic effect in a number of tumor cells." | 1.72 | Enhanced antitumor activity of combined methotrexate and histone deacetylase inhibitor valproic acid on mammary cancer in vitro and in vivo. ( Badary, OA; El Said, HH; El-Khatib, AS; Elmazar, MM; Shouman, SA, 2022) |
| "Valproic acid (VPA) was combined with gemcitabine (GCb) to stimulate EBV reactivation, followed by antiviral treatment with ganciclovir (GCV)." | 1.46 | Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model. ( de Greeuw, I; Eersels, JLH; Greijer, AE; Middeldorp, JM; Molthoff, CFM; Novalić, Z; Verkuijlen, SAWM; Verlaan, M, 2017) |
| "Valproic acid did not increase PTX-induced α-tubulin acetylation." | 1.43 | Valproic Acid as a Promising Co-Treatment With Paclitaxel and Doxorubicin in Different Ovarian Carcinoma Cell Lines. ( Fiedor, E; Gregoraszczuk, EL; Grzyb, E; Kwiecińska, P; Ptak, A; Taubøll, E, 2016) |
| "Four colon cancer cell lines with different phenotypes in regards to tumorigenicity, microsatellite stability and DNA mutation were used." | 1.42 | HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. ( Ji, M; Kim, DS; Kim, KB; Kim, Y; Lee, EJ; Lee, SJ; Park, SM; Sung, R, 2015) |
| "Choroid plexus carcinomas are rare tumors that typically occur in young children." | 1.35 | Histone acetylation resulting in resistance to methotrexate in choroid plexus cells. ( Das, CM; Gopalakrishnan, V; Prasad, P; Vasquez, H; Wolff, JE, 2009) |
| "Valproic acid is a well-known antiepileptic drug that was recently discovered to have a wide-spectrum antitumoral action in several tumors." | 1.33 | Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. ( Angelucci, A; Bernardini, S; Bologna, M; Dolo, V; Federici, G; Gravina, GL; Miano, R; Millimaggi, D; Valentini, A; Vicentini, C, 2006) |
| "In poorly differentiated thyroid cancer, molecular characteristics are reported to be lost such as to cause insensitivity of the tumor to radiometabolic therapy." | 1.32 | Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. ( Arena, K; Boccuzzi, G; Brignardello, E; Catalano, MG; Fortunati, N; Piovesan, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| El Said, HH | 1 |
| Badary, OA | 1 |
| Shouman, SA | 1 |
| Elmazar, MM | 1 |
| El-Khatib, AS | 1 |
| Novalić, Z | 3 |
| Verkuijlen, SAWM | 1 |
| Verlaan, M | 1 |
| Eersels, JLH | 1 |
| de Greeuw, I | 1 |
| Molthoff, CFM | 1 |
| Middeldorp, JM | 3 |
| Greijer, AE | 3 |
| Tsai, C | 1 |
| Leslie, JS | 1 |
| Franko-Tobin, LG | 1 |
| Prasnal, MC | 1 |
| Yang, T | 1 |
| Vienna Mackey, L | 1 |
| Fuselier, JA | 1 |
| Coy, DH | 1 |
| Liu, M | 1 |
| Yu, C | 1 |
| Sun, L | 1 |
| Juengel, E | 1 |
| Meyer dos Santos, S | 1 |
| Schneider, T | 1 |
| Makarevic, J | 1 |
| Hudak, L | 1 |
| Bartsch, G | 1 |
| Haferkamp, A | 1 |
| Wiesner, C | 1 |
| Blaheta, RA | 1 |
| Li, J | 2 |
| Bonifati, S | 1 |
| Hristov, G | 1 |
| Marttila, T | 1 |
| Valmary-Degano, S | 1 |
| Stanzel, S | 1 |
| Schnölzer, M | 1 |
| Mougin, C | 1 |
| Aprahamian, M | 1 |
| Grekova, SP | 1 |
| Raykov, Z | 1 |
| Rommelaere, J | 1 |
| Marchini, A | 1 |
| Ji, M | 1 |
| Lee, EJ | 1 |
| Kim, KB | 1 |
| Kim, Y | 1 |
| Sung, R | 1 |
| Lee, SJ | 1 |
| Kim, DS | 1 |
| Park, SM | 1 |
| Stoker, SD | 1 |
| Wildeman, MA | 2 |
| Huitema, AD | 2 |
| Verkuijlen, SA | 2 |
| Juwana, H | 2 |
| Tan, IB | 2 |
| de Boer, JP | 2 |
| Xu, Y | 1 |
| Xu, D | 1 |
| Zhu, SJ | 1 |
| Ye, B | 1 |
| Dong, JD | 1 |
| Zhang, YL | 1 |
| Zhang, Y | 1 |
| Strazzulla, A | 1 |
| Barreca, GS | 1 |
| Giancotti, A | 1 |
| Pisani, V | 1 |
| Costa, C | 1 |
| Zicca, E | 1 |
| La Boria, A | 1 |
| Roveda, L | 1 |
| Liberto, MC | 1 |
| Tucci, L | 1 |
| Donato, G | 1 |
| Focà, A | 1 |
| Torti, C | 1 |
| Hsu, CL | 1 |
| Kuo, YC | 1 |
| Huang, Y | 1 |
| Huang, YC | 1 |
| Lui, KW | 1 |
| Chang, KP | 1 |
| Lin, TL | 1 |
| Fan, HC | 1 |
| Lin, AC | 1 |
| Hsieh, CH | 1 |
| Lee, LY | 1 |
| Wang, HM | 1 |
| Li, HP | 1 |
| Chang, YS | 1 |
| Cha, HY | 1 |
| Lee, BS | 1 |
| Chang, JW | 1 |
| Park, JK | 1 |
| Han, JH | 1 |
| Kim, YS | 1 |
| Shin, YS | 1 |
| Byeon, HK | 1 |
| Kim, CH | 1 |
| Kwiecińska, P | 1 |
| Taubøll, E | 1 |
| Grzyb, E | 1 |
| Fiedor, E | 1 |
| Ptak, A | 1 |
| Gregoraszczuk, EL | 1 |
| Prasad, P | 1 |
| Vasquez, H | 1 |
| Das, CM | 1 |
| Gopalakrishnan, V | 1 |
| Wolff, JE | 1 |
| Noguchi, H | 1 |
| Yamashita, H | 1 |
| Murakami, T | 1 |
| Hirai, K | 1 |
| Noguchi, Y | 1 |
| Maruta, J | 1 |
| Yokoi, T | 1 |
| Noguchi, S | 1 |
| Kim, TH | 1 |
| Yoo, YH | 1 |
| Kang, DY | 1 |
| Suh, H | 1 |
| Park, MK | 1 |
| Park, KJ | 1 |
| Kim, SH | 1 |
| Hui, KF | 1 |
| Chiang, AK | 1 |
| De la Cruz-Hernández, E | 1 |
| Perez-Plasencia, C | 1 |
| Pérez-Cardenas, E | 1 |
| Gonzalez-Fierro, A | 1 |
| Trejo-Becerril, C | 1 |
| Chávez-Blanco, A | 1 |
| Taja-Chayeb, L | 1 |
| Vidal, S | 1 |
| Gutiérrez, O | 1 |
| Dominguez, GI | 1 |
| Trujillo, JE | 1 |
| Duenas-González, A | 1 |
| Yi, TZ | 1 |
| Han, X | 1 |
| Guo, J | 1 |
| Qu, Q | 1 |
| Guo, L | 1 |
| Sun, HD | 1 |
| Tan, WH | 1 |
| Fortunati, N | 3 |
| Catalano, MG | 3 |
| Arena, K | 1 |
| Brignardello, E | 1 |
| Piovesan, A | 1 |
| Boccuzzi, G | 3 |
| Angelucci, A | 1 |
| Valentini, A | 1 |
| Millimaggi, D | 1 |
| Gravina, GL | 1 |
| Miano, R | 1 |
| Dolo, V | 1 |
| Vicentini, C | 1 |
| Bologna, M | 1 |
| Federici, G | 1 |
| Bernardini, S | 1 |
| Pugliese, M | 2 |
| Poli, R | 2 |
| Bosco, O | 1 |
| Mastrocola, R | 1 |
| Aragno, M | 1 |
| Schwartz, C | 1 |
| Palissot, V | 1 |
| Aouali, N | 1 |
| Wack, S | 1 |
| Brons, NH | 1 |
| Leners, B | 1 |
| Bosseler, M | 1 |
| Berchem, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma[NCT02761291] | Phase 1 | 18 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for valproic acid and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Nasopharyngeal carcinoma: review of the literature with a focus on therapeutical implications.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, | 2015 |
1 trial available for valproic acid and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.
Topics: Adult; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; | 2015 |
22 other studies available for valproic acid and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Enhanced antitumor activity of combined methotrexate and histone deacetylase inhibitor valproic acid on mammary cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Histone Deacetylase Inhibito | 2022 |
Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Topics: Animals; Antiviral Agents; Carcinoma; Deoxycytidine; Disease Models, Animal; DNA, Viral; Epstein-Bar | 2017 |
Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II.
Topics: Animals; Anticonvulsants; Carcinoma; Cell Differentiation; Cell Proliferation; Colchicine; Cyclin-De | 2013 |
HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions.
Topics: Carcinoma; Cell Adhesion; Cell Line, Tumor; Collagen; Flow Cytometry; Histone Deacetylase Inhibitors | 2013 |
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
Topics: Animals; Apoptosis; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Female; HeLa Cells; Histone | 2013 |
HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells.
Topics: Cadherins; Carcinoma; Cell Movement; Colonic Neoplasms; Epithelial-Mesenchymal Transition; HCT116 Ce | 2015 |
Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA).
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma; Cell Line, Tumor; Cell Proliferation; Chloro | 2015 |
Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Carcinoma; C | 2015 |
Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Carcinoma; Carcin | 2016 |
Valproic Acid as a Promising Co-Treatment With Paclitaxel and Doxorubicin in Different Ovarian Carcinoma Cell Lines.
Topics: Acetylation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Caspa | 2016 |
Histone acetylation resulting in resistance to methotrexate in choroid plexus cells.
Topics: Acetylation; Animals; Antigens, Viral, Tumor; Apoptosis; Benzamides; Carcinoma; Cell Line, Transform | 2009 |
Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery.
Topics: Carcinoma; Cisplatin; Combined Modality Therapy; Doxorubicin; Humans; Male; Middle Aged; Thyroid Gla | 2009 |
Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Survival; | 2009 |
Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Burkitt Lymphoma; Butyrates; Carcinoma; Cell Cy | 2010 |
Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; DNA Methylation | 2011 |
DNMT inhibitors and HDAC inhibitors regulate E-cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cadherins; Carcinoma; Cell Cycle Checkpoints | 2012 |
Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
Topics: Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Deox | 2012 |
Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells.
Topics: Carcinoma; Carcinoma, Papillary; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, | 2004 |
Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Fas Ligand Protei | 2006 |
Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Topics: Acetylation; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carcinoma; Caspase 3; Cell Cycle; | 2006 |
Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines.
Topics: Apoptosis; Cadaverine; Carcinoma; Caspases; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; | 2007 |
Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.
Topics: Acetylation; Acetyltransferases; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2007 |